Clinical evaluation of celiprolol hydrochloride (Selectol®) to the hypertensive patients with type 2 diabetes - Combination therapy with Ca2+antagonist and/or ACE inhibitor

Shu Meguro, Takei Izumi

Research output: Contribution to journalArticle

Abstract

The aim of this study was to confirm the clinical efficacy, metabolic effects and safety of celiprolol, a selective β1-blocker with β2 agonist property, to essential hypertensive patients with diabetes aged 53 to 92 years (mean, 70 years), recognized insufficient antihypertensive effects by Ca2+antagonist and/or ACE inhibitor. Fifteen patients were administered celiprolol at daily dose of 100∼200 mg during six months. The obtained results were followed. Blood pressure decreased significantly from 164.8 ± 5.8/92.8 ± 3.0 mmHg to 151.7 ± 3.8/84.7 ± 3.6 mmHg after six months of treatment, respectively (p<0.05). On the oral glucose tolerance test, celiplorol had no influence to values of blood sugar and blood insulin. As well as HbA1c and Body mass index, no significant changes were observed. Total cholesterol and triglyceride decreased significantly from 218.9 ± 10.4 mg/dL and 125.3 ± 12.9 mg/dL to 193.8 ± 10.4 mg/dL and 88.6 ± 4.1 mg/dL, respectively (p<0.05). HDL cholesterol increased from 52.9 ± 3.8 mg/dL at the before treatment to 54.4 ± 6.9 mg/dL at the six months after treatment, but not significant. No side effcts were noted in all patients. The above results indicated that celiprolol is useful β-blocker to essential hypertensive patients with type 2 diabetes.

Original languageEnglish
Pages (from-to)1649-1655
Number of pages7
JournalTherapeutic Research
Volume23
Issue number8
Publication statusPublished - 2002

Fingerprint

Celiprolol
Angiotensin-Converting Enzyme Inhibitors
Type 2 Diabetes Mellitus
Therapeutics
Glucose Tolerance Test
HDL Cholesterol
Antihypertensive Agents
Blood Glucose
Triglycerides
Body Mass Index
Cholesterol
Insulin
Blood Pressure
Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{1cc3016e14344a749ae6f8919cd75cd0,
title = "Clinical evaluation of celiprolol hydrochloride (Selectol{\circledR}) to the hypertensive patients with type 2 diabetes - Combination therapy with Ca2+antagonist and/or ACE inhibitor",
abstract = "The aim of this study was to confirm the clinical efficacy, metabolic effects and safety of celiprolol, a selective β1-blocker with β2 agonist property, to essential hypertensive patients with diabetes aged 53 to 92 years (mean, 70 years), recognized insufficient antihypertensive effects by Ca2+antagonist and/or ACE inhibitor. Fifteen patients were administered celiprolol at daily dose of 100∼200 mg during six months. The obtained results were followed. Blood pressure decreased significantly from 164.8 ± 5.8/92.8 ± 3.0 mmHg to 151.7 ± 3.8/84.7 ± 3.6 mmHg after six months of treatment, respectively (p<0.05). On the oral glucose tolerance test, celiplorol had no influence to values of blood sugar and blood insulin. As well as HbA1c and Body mass index, no significant changes were observed. Total cholesterol and triglyceride decreased significantly from 218.9 ± 10.4 mg/dL and 125.3 ± 12.9 mg/dL to 193.8 ± 10.4 mg/dL and 88.6 ± 4.1 mg/dL, respectively (p<0.05). HDL cholesterol increased from 52.9 ± 3.8 mg/dL at the before treatment to 54.4 ± 6.9 mg/dL at the six months after treatment, but not significant. No side effcts were noted in all patients. The above results indicated that celiprolol is useful β-blocker to essential hypertensive patients with type 2 diabetes.",
author = "Shu Meguro and Takei Izumi",
year = "2002",
language = "English",
volume = "23",
pages = "1649--1655",
journal = "Therapeutic Research",
issn = "0289-8020",
publisher = "Life Science Publishing Co. Ltd",
number = "8",

}

TY - JOUR

T1 - Clinical evaluation of celiprolol hydrochloride (Selectol®) to the hypertensive patients with type 2 diabetes - Combination therapy with Ca2+antagonist and/or ACE inhibitor

AU - Meguro, Shu

AU - Izumi, Takei

PY - 2002

Y1 - 2002

N2 - The aim of this study was to confirm the clinical efficacy, metabolic effects and safety of celiprolol, a selective β1-blocker with β2 agonist property, to essential hypertensive patients with diabetes aged 53 to 92 years (mean, 70 years), recognized insufficient antihypertensive effects by Ca2+antagonist and/or ACE inhibitor. Fifteen patients were administered celiprolol at daily dose of 100∼200 mg during six months. The obtained results were followed. Blood pressure decreased significantly from 164.8 ± 5.8/92.8 ± 3.0 mmHg to 151.7 ± 3.8/84.7 ± 3.6 mmHg after six months of treatment, respectively (p<0.05). On the oral glucose tolerance test, celiplorol had no influence to values of blood sugar and blood insulin. As well as HbA1c and Body mass index, no significant changes were observed. Total cholesterol and triglyceride decreased significantly from 218.9 ± 10.4 mg/dL and 125.3 ± 12.9 mg/dL to 193.8 ± 10.4 mg/dL and 88.6 ± 4.1 mg/dL, respectively (p<0.05). HDL cholesterol increased from 52.9 ± 3.8 mg/dL at the before treatment to 54.4 ± 6.9 mg/dL at the six months after treatment, but not significant. No side effcts were noted in all patients. The above results indicated that celiprolol is useful β-blocker to essential hypertensive patients with type 2 diabetes.

AB - The aim of this study was to confirm the clinical efficacy, metabolic effects and safety of celiprolol, a selective β1-blocker with β2 agonist property, to essential hypertensive patients with diabetes aged 53 to 92 years (mean, 70 years), recognized insufficient antihypertensive effects by Ca2+antagonist and/or ACE inhibitor. Fifteen patients were administered celiprolol at daily dose of 100∼200 mg during six months. The obtained results were followed. Blood pressure decreased significantly from 164.8 ± 5.8/92.8 ± 3.0 mmHg to 151.7 ± 3.8/84.7 ± 3.6 mmHg after six months of treatment, respectively (p<0.05). On the oral glucose tolerance test, celiplorol had no influence to values of blood sugar and blood insulin. As well as HbA1c and Body mass index, no significant changes were observed. Total cholesterol and triglyceride decreased significantly from 218.9 ± 10.4 mg/dL and 125.3 ± 12.9 mg/dL to 193.8 ± 10.4 mg/dL and 88.6 ± 4.1 mg/dL, respectively (p<0.05). HDL cholesterol increased from 52.9 ± 3.8 mg/dL at the before treatment to 54.4 ± 6.9 mg/dL at the six months after treatment, but not significant. No side effcts were noted in all patients. The above results indicated that celiprolol is useful β-blocker to essential hypertensive patients with type 2 diabetes.

UR - http://www.scopus.com/inward/record.url?scp=0036033746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036033746&partnerID=8YFLogxK

M3 - Article

VL - 23

SP - 1649

EP - 1655

JO - Therapeutic Research

JF - Therapeutic Research

SN - 0289-8020

IS - 8

ER -